Pomerantz Appointed Co-Lead Counsel in Centessa Pharmaceuticals Securities Litigation

On December 12, 2022, U.S. Magistrate Judge Sarah L. Cave, of the Southern District of New York, appointed Pomerantz LLP as Co-Lead Counsel on behalf of its client, Jamia Fernandes, who serves as the Co-Lead Plaintiff, and the class, in Fernandes v. Centessa Pharmaceuticals PLC, 22-cv-8805 (S.D.N.Y.). This securities action alleges that Centessa Pharmaceuticals plc misled the market regarding the safety and commercial prospects for lixivaptan and ZF874, two of the drugs in its development pipeline. Centessa is a clinical-stage biopharmaceutical company that develops and delivers medicines to patients. The Company’s development pipeline includes lixivaptan, a vasopressin V2…